GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Johnson & Johnson (BSP:JNJB34) » Definitions » Cyclically Adjusted PS Ratio

Johnson & Johnson (BSP:JNJB34) Cyclically Adjusted PS Ratio : 4.46 (As of May. 23, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Johnson & Johnson Cyclically Adjusted PS Ratio?

As of today (2024-05-23), Johnson & Johnson's current share price is R$52.70. Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$11.82. Johnson & Johnson's Cyclically Adjusted PS Ratio for today is 4.46.

The historical rank and industry rank for Johnson & Johnson's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:JNJB34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 3.74   Med: 4.82   Max: 5.9
Current: 4.35

During the past years, Johnson & Johnson's highest Cyclically Adjusted PS Ratio was 5.90. The lowest was 3.74. And the median was 4.82.

BSP:JNJB34's Cyclically Adjusted PS Ratio is ranked worse than
76.61% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.12 vs BSP:JNJB34: 4.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Johnson & Johnson's adjusted revenue per share data for the three months ended in Mar. 2024 was R$2.921. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$11.82 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Johnson & Johnson Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Johnson & Johnson's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Johnson & Johnson Cyclically Adjusted PS Ratio Chart

Johnson & Johnson Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.21 5.46 5.52 5.32 4.53

Johnson & Johnson Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.59 4.82 4.49 4.53 4.49

Competitive Comparison of Johnson & Johnson's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Johnson & Johnson's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Johnson & Johnson's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Johnson & Johnson's Cyclically Adjusted PS Ratio falls into.



Johnson & Johnson Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Johnson & Johnson's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=52.70/11.82
=4.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Johnson & Johnson's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.921/131.7762*131.7762
=2.921

Current CPI (Mar. 2024) = 131.7762.

Johnson & Johnson Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.011 100.560 1.325
201409 1.005 100.428 1.319
201412 1.131 99.070 1.504
201503 1.288 99.621 1.704
201506 1.312 100.684 1.717
201509 1.585 100.392 2.081
201512 1.646 99.792 2.174
201603 1.537 100.470 2.016
201606 1.510 101.688 1.957
201609 1.388 101.861 1.796
201612 1.464 101.863 1.894
201703 1.345 102.862 1.723
201706 1.510 103.349 1.925
201709 1.499 104.136 1.897
201712 1.618 104.011 2.050
201803 1.601 105.290 2.004
201806 1.924 106.317 2.385
201809 2.043 106.507 2.528
201812 1.937 105.998 2.408
201903 1.899 107.251 2.333
201906 1.964 108.070 2.395
201909 2.132 108.329 2.593
201912 2.124 108.420 2.582
202003 2.523 108.902 3.053
202006 2.379 108.767 2.882
202009 2.843 109.815 3.412
202012 2.887 109.897 3.462
202103 3.137 111.754 3.699
202106 2.925 114.631 3.362
202109 3.071 115.734 3.497
202112 1.378 117.630 1.544
202203 2.915 121.301 3.167
202206 3.030 125.017 3.194
202209 2.627 125.227 2.764
202212 2.628 125.222 2.766
202303 2.785 127.348 2.882
202306 3.146 128.729 3.220
202309 2.757 129.860 2.798
202312 2.874 129.419 2.926
202403 2.921 131.776 2.921

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Johnson & Johnson  (BSP:JNJB34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Johnson & Johnson Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Johnson & Johnson's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Johnson & Johnson (BSP:JNJB34) Business Description

Address
One Johnson and Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson (BSP:JNJB34) Headlines

No Headlines